@article{db08461a00ee4cf0b45a8a975a214168,
title = "Mapping creatinine- and cystatin C-related white matter brain deficits in the elderly",
abstract = "Poor kidney function is associated with increased risk of cognitive decline and generalized brain atrophy. Chronic kidney disease impairs glomerular filtration rate, and this deterioration is indicated by elevated blood levels of kidney biomarkers such as creatinine and cystatin C. Here we hypothesized that impaired renal function would be associated with brain deficits in regions vulnerable to neurodegeneration. Using tensor-based morphometry, we related patterns of brain volumetric differences to creatinine, cystatin C levels, and glomerular filtration rate in a large cohort of 738 (mean age, 75.5 ± 6.8 years; 438 men, 300 women) elderly Caucasian subjects scanned as part of the Alzheimer's Disease Neuroimaging Initiative. Elevated kidney biomarkers were associated with volume deficits in the white matter region of the brain. All 3 renal parameters in our study showed significant associations consistently with a region that corresponds with the anterior limb of internal capsule, bilaterally. This is the first study to report a marked profile of structural alterations in the brain associated with elevated kidney biomarkers, helping us to explain the cognitive deficits.",
keywords = "Brain atrophy, Brain structure, Brain volumes, Cognitive deficits, Creatinine, Cystatin C, GFR, Kidney function, Neuroimaging",
author = "Priya Rajagopalan and Helga Refsum and Xue Hua and Toga, {Arthur W.} and Jack, {Clifford R.} and Weiner, {Michael W.} and Thompson, {Paul M.}",
note = "Funding Information: This work was supported by NIH grants U01 AG024904, R01 EB008281 and R01 AG020098 to PT. ADNI data collection was funded by the Alzheimer's Disease Neuroimaging Initiative (ADNI; NIH Grant U01 AG024904 ). ADNI is funded by the National Institute on Aging , the National Institute of Biomedical Imaging and Bioengineering , Abbott , AstraZeneca AB , Bayer Schering Pharma AG , Bristol-Myers Squibb , Eisai Global Clinical Development , Elan Corporation , Genentech , GE Healthcare , GlaxoSmithKline , Innogenetics , Johnson and Johnson , Eli Lilly and Co , Medpace, Inc , Merck and Co, Inc , Novartis AG, Pfizer Inc , F. Hoffman-La Roche , Schering-Plough, Synarc, Inc , Wyeth , and non-profit partners the Alzheimer's Association and Alzheimer's Drug Discovery Foundation , with participation from the U.S. Food and Drug Administration . Private sector contributions to ADNI are facilitated by the Foundation for the National Institutes of Health ( www.fnih.org ). The grantee organization is the Northern California Institute for Research and Education , and the study is coordinated by the Alzheimer's Disease Cooperative Study at the University of California, San Diego. ADNI research was also supported by NIH grants P30 AG010129, K01 AG030514 , and the Dana Foundation . ADNI data are disseminated by the Laboratory for Neuro Imaging at the University of California, Los Angeles.",
year = "2013",
month = apr,
doi = "10.1016/j.neurobiolaging.2012.10.022",
language = "English (US)",
volume = "34",
pages = "1221--1230",
journal = "Neurobiology of aging",
issn = "0197-4580",
publisher = "Elsevier Inc.",
number = "4",
}